PMID- 22778735
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20120823
LR  - 20211021
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Print)
IS  - 1687-8450 (Linking)
VI  - 2012
DP  - 2012
TI  - Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the 
      head and neck.
PG  - 521215
LID - 10.1155/2012/521215 [doi]
LID - 521215
AB  - Squamous cell carcinoma of head and neck (SCCHN) is the most common neoplasm of 
      the upper aerodigestive tract. In this paper, we attempt to summarize the role 
      and applications of the epidermal growth factor receptor (EGFR) inhibitors 
      monoclonal antibodies (moAbs) and tyrosine kinase inhibitors (TKIs) locally 
      advanced as well as metastatic SCCHN. Targeted therapy in SCCHN is now 
      incorporated in the first-line regimes for advanced disease. Novel targeted 
      agents, including the EGFR antibody, cetuximab, have been approved for use as 
      single agents or in combination with radiation therapy or chemotherapy in 
      treatment of recurrent metastatic or locally advanced SCCHN. Refractory 
      mechanisms that bypass the pathway of EGFR inhibitors activity are identified 
      explaining resistance to targeted therapy. Strategies of cotargeting EGFR and 
      other pathways are under investigation. Examples of targeted therapy being used 
      include mammalian target of rapamycin (mtor) inhibitors, antivascular endothelial 
      growth factor (VEGF) moAb, and other inhibitors. We will be focusing our paper on 
      the preclinical and clinical aspects of EGFR inhibition in SCCHN and touch upon 
      other targeted therapies in application.
FAU - Shaib, Walid
AU  - Shaib W
AD  - Winship Cancer Institute, Emory University, 1365 Clifton Road Northeast Atlanta, 
      GA 30322, USA.
FAU - Kono, Scott
AU  - Kono S
FAU - Saba, Nabil
AU  - Saba N
LA  - eng
PT  - Journal Article
DEP - 20120619
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC3388373
EDAT- 2012/07/11 06:00
MHDA- 2012/07/11 06:01
PMCR- 2012/06/19
CRDT- 2012/07/11 06:00
PHST- 2012/01/12 00:00 [received]
PHST- 2012/04/19 00:00 [accepted]
PHST- 2012/07/11 06:00 [entrez]
PHST- 2012/07/11 06:00 [pubmed]
PHST- 2012/07/11 06:01 [medline]
PHST- 2012/06/19 00:00 [pmc-release]
AID - 10.1155/2012/521215 [doi]
PST - ppublish
SO  - J Oncol. 2012;2012:521215. doi: 10.1155/2012/521215. Epub 2012 Jun 19.